8-K: Zynex Shifts NiCO Strategy, Incurs $31M Impairment

Zynex, Inc. announced a strategic shift for its NiCO CO-Oximeter, seeking a commercialization partner and incurring up to $31 million in impairment charges.

Summary

• Zynex, Inc. has decided to seek a commercialization partner for its NiCO CO-Oximeter, developed by its wholly-owned subsidiary, Zynex Monitoring Solutions, Inc. (ZMS), instead of pursuing independent commercialization.
• The company previously submitted a 510(k) application for the NiCO device to the U.S. Food and Drug Administration.
• On October 1, 2025, Zynex terminated the positions of a majority of ZMS employees, expecting substantial cost savings from this reduction in force.
• Zynex anticipates incurring pre-tax cash charges of approximately $0.1 million for severance payments to former ZMS employees, expected to be recognized in the fourth quarter of 2025.
• The company also expects pre-tax non-cash asset impairment charges of up to approximately $31.0 million, primarily related to goodwill and other assets associated with the ZMS business, expected to be recognized in the third quarter of 2025.

Sentiment

Score: 3

Explanation: The sentiment is negative due to significant impairment charges and employee terminations, reflecting a setback in the independent commercialization strategy for NiCO. While a strategic shift to find a partner could be positive long-term, the immediate financial impact and uncertainty weigh heavily.

Positives

• Expected substantial cost savings from the reduction in force at Zynex Monitoring Solutions, Inc.

Negatives

• Incurrence of up to $31.0 million in pre-tax non-cash asset impairment charges related to the ZMS business.
• Incurrence of approximately $0.1 million in pre-tax cash charges for severance payments.
• Termination of the majority of ZMS employees.
• Uncertainty regarding the success of attracting a commercialization partner for the NiCO CO-Oximeter.

Risks

• No assurance can be provided that the company will be successful in attracting a commercialization partner for the NiCO CO-Oximeter.
• Actual results could differ materially from forward-looking statements due to various risks and uncertainties, including those identified in the company's Annual Report on Form 10-K/A for the fiscal year ended December 31, 2024, and Quarterly Report on Form 10-Q for the period ended June 30, 2025.

Future Outlook

The company will continue to pursue commercialization opportunities with third-parties for the NiCO CO-Oximeter, following a strategic shift away from independent commercialization. Substantial cost savings are expected from the reduction in force, though there is no assurance of successfully attracting a commercialization partner.

Management Comments

• The company has decided to seek a commercialization partner for the NiCO CO-Oximeter, rather than pursue commercialization independently.
• The company will continue to pursue commercialization opportunities with third-parties for NiCO.

Industry Context

This strategic shift reflects the challenges often faced by medical device companies in independently commercializing new products, particularly those requiring significant regulatory and market penetration efforts. Seeking a commercialization partner is a common strategy to leverage established distribution networks and expertise, potentially mitigating direct operational costs and risks for the developer.

Stakeholder Impact

• Shareholders: Will be impacted by the significant non-cash impairment charges and the uncertainty surrounding the future commercialization success of the NiCO CO-Oximeter.
• Employees: A majority of ZMS employees have been terminated, leading to job losses and severance payments.

Next Steps

• Recognize pre-tax non-cash asset impairment charges in the third quarter of 2025.
• Recognize pre-tax cash charges for severance payments in the fourth quarter of 2025.
• Actively pursue commercialization opportunities with third-parties for the NiCO CO-Oximeter.

Key Dates

Recommendation

The immediate financial impact of up to $31 million in impairment charges and $0.1 million in severance, coupled with the termination of a majority of ZMS employees, presents a clear negative signal. However, the strategic shift to seek a commercialization partner, while uncertain, could potentially unlock value for the NiCO CO-Oximeter without Zynex incurring further direct commercialization costs. A 'hold' recommendation allows investors to observe the company's success in securing a partner and the actual 'substantial cost savings' before making a definitive 'buy' or 'sell' decision, acknowledging both the immediate downside and potential future upside.

Keywords

Zynex, ZYXI, NiCO CO-Oximeter, Zynex Monitoring Solutions, medical device, impairment, restructuring, strategic shift, severance, FDA 510(k)